APTO - Aptose inks exclusive license agreement with Hanmi Pharmaceutical

Aptose Biosciences (NASDAQ:APTO) has entered into an exclusive license agreement with Hanmi Pharmaceutical to develop and commercialize HM43239, designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others. Hanmi will receive an upfront payment of $12.5M, including $5M in cash and $7.5M in Aptose shares. Under the terms of the agreement, Hanmi has granted Aptose exclusive worldwide rights to HM43239 for all indications. Hanmi will also receive up to $407.5M in future milestone payments contingent upon the achievement of certain clinical, regulatory and sales milestones across several potential indications, as well as tiered royalties on net sales. HM43239 has showed significant genotype-agnostic anti-leukemic activity in an ongoing Phase 1/2 clinical trial, including multiple complete responses in patients with relapsed or refractory acute myeloid leukemia (AML), the company said. Aptose shares up more than 1% premarket.

For further details see:

Aptose inks exclusive license agreement with Hanmi Pharmaceutical